canberra_new_virtual

Due to the complexities of the pandemic, this event was fully virtual and on Canberra, Australia time zone on January 12-14, 2021. Oncology and supportive care: a multidisciplinary approach to advance the science of cancer treatment in older patients

The SIOG Advanced Course in Geriatric Oncology focuses on a multi-disciplinary training of experts for the treatment of older cancer patients. In an effort to stimulate learning and interaction, the course covers general principles of cancer treatment using case-based discussions and debates.

Delegates will benefit from a course format that encourages student-faculty interactions. The lectures will cover themes in geriatrics for clinical oncologists as well as in clinical oncology for geriatricians, including direct patient care modules for nurses and allied health professionals.

Download the SIOG 2021 Advanced Course Programme (pdf)

“The SIOG 2021 Advanced Course in Geriatric Oncology – Virtual, Canberra, Virtual, Australia, 12/01/2021-13/01/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.”

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”

Platinum Sponsor

Pfizer Australia
Pfizer Oncology works collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners to further its extensive research and development program. We are committed to partnerships with professional and patient organisations that deliver benefits to patients including disease management tools, awareness of clinical trial options and access to new medicines.
Working together, we strive to transform treatment by targeting the right drug for the right patient at the right time.
For more information about Pfizer Oncology, please visit www.pfizer.com.au

Bronze Sponsors

Roche Australia
 Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.

Janssen Australia and New Zealand (Janssen-Cilag Pty Ltd)
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more about Janssen at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Australia and New Zealand (Janssen-Cilag Pty Ltd) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Supporting Sponsors